cefradine

Small moleculeapproved

Approved

Aug 19, 1974

Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 8 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 31, 2010 (NCT01312792)

Timeline

1970s

Aug 19, 1974
Earliest FDA Approval
Aug 19, 1974
Apothecon — Marketing Organization
Oct 1, 1974
GlaxoSmithKline — Marketing Organization

1980s

Jan 9, 1987
Teva — Marketing Organization
Apr 22, 1988
Barr Laboratories — Marketing Organization

Indications

Approved for

Mechanism of action

Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor

Approval history

approvedAug 19, 1974

Chemistry & pharmacology

Loading structure…

SMILES

CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O

Mol. weight: 349.405 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral, Parenteral
Availability: Discontinued

Oral

Yes

Parenteral

Yes

Topical

Sources

Also known as

(6r,7r)-7-{[(2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-{[(2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
7-(d-2-amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid
7-(d-2-amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid
anspor
anspor
anspor
ced
ced
cefradex
cefradin
cefradina
cefradina
cefradine
cefradine
cefradine
cefradine
cefradine
cefradine
cefradine
cefradine
cefradinum
cefradinum
cephradin
cephradin
cephradin
cephradine
cephradine
cephradine
cephradine
cephradine
cephradine
cephradine
ecosporina
eskacef
eskacef
nicef
nicef
sefril
sefril
sk-d-39304
sk-d-39304
sk&f-d39304
sk&f-d39304
sq-11436
sq-11436
sq-22022
sq-22022
sq-22022 [dihydrate]
sq-22022 [dihydrate]
velosef
velosef
velosef
velosef '125'
velosef '125'
velosef '250'
velosef '250'
velosef '500'
velosef '500'

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01312792	N/A	Aug 31, 2010	International Center for Diarrheal Disease Research, United Nations

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
International Center for Diarrheal Disease Research	Academic/Hospital	1	1	1	2010
United Nations	Government	1	0	1	2010

2 organizations

Page 1 / 1

Marketing (8)

Organization	Org type	Relationship	Date
Apothecon	For profit	MKTG	Aug 19, 1974
Barr Laboratories	For profit	MKTG	Apr 22, 1988
Bristol-Myers Squibb	For profit	NDA2	—
ERSANA	For profit	NDA2	—
GlaxoSmithKline	For profit	MKTG	Oct 1, 1974
Squibb	For profit	NDA	—
Teva	For profit	MKTG	Jan 9, 1987
Vitarine	For profit	MKTG	—